Fedin-20 (piroxicam) capsules 20 mg. №30

$11.40

Manufacturer: India

Symptomatic treatment of osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis. Due to the safety profile, piroxicam is not the first choice if other non-steroidal anti-inflammatory or anti-rheumatic agents are indicated. The decision to prescribe piroxicam should be based on an assessment of the individual’s overall risk to the patient.

Category:

Description

Fedin-20 Storage
active substance: piroxicam;

1 capsule contains piroxicam 20 mg;

Excipients: lactose monohydrate, corn starch, colloidal anhydrous silica.

Fedin-20 Dosage form
Capsules.

Main physical and chemical properties: hard gelatin capsules number 2, body and lid red, on the body and lid is imprinted “FEDIN 20”.

The capsules contain a white or almost white powder.

Fedin-20 Pharmacotherapeutic group
Nonsteroidal anti-inflammatory and anti-rheumatic drugs. Derivatives of oxicams.

ATX code M01A C01.

Pharmacological properties

Pharmacodynamics.

Pharmacological action – anti-inflammatory, analgesic, antipyretic, antiplatelet. Reduces the synthesis of prostaglandins (PG), including PGE1, PGE2, PGE2-alpha and thromboxanes by inhibiting the activity of cyclooxygenase. Inhibits phagocytosis, platelet aggregation. Helps relieve pain, symptoms of inflammation. With joint syndrome, it weakens or stops inflammation and pain in the joints at rest and when moving, reduces morning stiffness and swelling of the joints.

Pharmacokinetics.

When taken orally, it is well absorbed from the gastrointestinal tract, the maximum concentration is reached in 3-5 hours. Equilibrium concentration in the blood is reached within 7-12 days. Plasma protein binding is 97-99%. When used concomitantly with other drugs, it can displace them when bound to proteins, as a result, may enhance their therapeutic effect. Penetrates the placental and blood-brain barrier. Excreted in breast milk. Metabolized in the liver, the main metabolites – 5-hydroxypyroxicam, N-methyl-benzosulfonamide and others – are pharmacologically inactive. The half-life is about 50 hours, may increase in liver disease. It is excreted by the kidneys and through the gastrointestinal tract (in the urine is determined by 2 times more than in the feces) mainly in the form of glucuronides (5% is excreted unchanged). Does not accumulate.

Indication
Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis.

Due to the safety profile, piroxicam is not the first choice if other nonsteroidal anti-inflammatory or anti-rheumatic drugs are indicated. The decision to prescribe piroxicam should be based on an assessment of the individual’s overall risk to the patient.

Contraindication
The use is contraindicated in:

gastrointestinal ulcers, history of bleeding or perforation;
a history of gastrointestinal disorders that can lead to bleeding, such as ulcerative colitis, Crohn’s disease, gastrointestinal cancer or diverticulitis;
active peptic ulcer, inflammatory gastrointestinal diseases or gastrointestinal bleeding;
hemorrhagic diathesis, changes in the blood picture of unclear genesis (including in the anamnesis);
concomitant use with other nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors and acetylsalicylic acid in analgesic doses;
concomitant use with anticoagulants;
history of serious allergic reactions of any type, especially skin reactions, such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis;
hypersensitivity to the active or excipients of the drug, transient skin reactions (regardless of their severity) in response to the use of piroxicam, other nonsteroidal anti-inflammatory and antirheumatic drugs and other drugs;
severe heart failure;
severe renal or hepatic failure;
use of acetylsalicylic acid and other NSAIDs in patients in whom the latter induced the development of bronchial asthma, allergic rhinitis, nasal polyps, angioneurotic edema and / or urticaria.